Study of Atenolol Influence on Blood Pressure During Resistance Exercise
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01030016 |
Recruitment Status :
Completed
First Posted : December 10, 2009
Last Update Posted : December 15, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Blood Pressure Exercise | Drug: atenolol | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | Non-Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Supportive Care |
Official Title: | Blood Pressure Response During Resistance Exercise in Hypertensives: Influence of Beta-blockers |
Study Start Date : | May 2007 |
Actual Primary Completion Date : | May 2009 |
Actual Study Completion Date : | May 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: atenolol
subjects received 6 weeks of atenolol
|
Drug: atenolol
25 mg/day, twice a day for 6 weeks
Other Name: beta-blockers |
- blood pressure during resistance exercise [ Time Frame: 6 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- hypertension with blood pressure levels below 160/105 mmHg under placebo.
- age between 30 and 60 years
- nonobese
Exclusion Criteria:
- target organ lesion
- cardiovascular risk factor
- cardiovascular disease
- physically active

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01030016
Brazil | |
University of São Paulo | |
São Paulo, Brazil, 05508030 |
Principal Investigator: | Cláudia LM Forjaz, PhD | University of São Paulo | |
Study Chair: | Decio Mion Jr, PhD | University of São Paulo |
Responsible Party: | Cláudia Lúcia de Moraes Forjaz, School of Physical Education and Sport, University of São Paulo |
ClinicalTrials.gov Identifier: | NCT01030016 History of Changes |
Other Study ID Numbers: |
FAPESP-06/06356-8 |
First Posted: | December 10, 2009 Key Record Dates |
Last Update Posted: | December 15, 2009 |
Last Verified: | May 2009 |
resistance exercise beta-blockers blood pressure |
Atenolol Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |
Anti-Arrhythmia Agents Antihypertensive Agents Sympatholytics Autonomic Agents Peripheral Nervous System Agents Adrenergic beta-1 Receptor Antagonists |